NEW YORK (GenomeWeb News) — Almac Diagnostics this week said it plans to meet with the US Food and Drug Administration about starting clinical trials of an array-based colorectal recurrence test it hopes to launch next year.
 
The Craigavon, UK-based company, which has to date offered arrays for research purposes, intends to launch the assays as an in vitro diagnostic if the FDA clears its 510(k) application.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.